CAJ | 학술논문

目的：探讨针对复发性卵巢癌患者，观察于CT引导下实施经皮穿刺灌注顺铂完成治疗后获得的临床效果。方法：选取我院2012年05月—2014年05月复发性卵巢癌患者42例。针对所有患者于CT引导下经腹皮选择粗针对卵巢肿瘤实施穿刺。成功完成置管后，对患者灌注剂量为20 mg的顺铂，1次/周，对患者不间断灌注4周后，完成拔管。对患者完成1个月的治疗之后，对患者血清CA125进行复查，并且对患者实施胸腹盆腔CT检查，选择RECIST疗效评价标准对患者最终的临床治疗效果实施评价。结果：对患者完成1个月的治疗后，在所有患者中，完全缓解患者5例，稳定患者36例，进展患者1例。患者近期总有效率为97.6%（41/42）。对患者进行为期2年的随访，患者无进展生存期时间为6～25个月，平均进展生存期时间为（12.3±0.1）个月。所有患者全部成功完成一次性穿刺，对患者临床实施手术的时间为26～47 min，平均时间为（36.5±1.2）min。结论：针对复发性卵巢癌患者，临床于 CT 引导下，选择经皮穿刺灌注顺铂进行治疗，最终于临床能够获得确切治疗效果，表现出较高的治疗安全性，凸显此种方法治疗复发性卵巢癌患者的临床价值。
목적：탐토침대복발성란소암환자，관찰우CT인도하실시경피천자관주순박완성치료후획득적림상효과。방법：선취아원2012년05월—2014년05월복발성란소암환자42례。침대소유환자우CT인도하경복피선택조침대란소종류실시천자。성공완성치관후，대환자관주제량위20 mg적순박，1차/주，대환자불간단관주4주후，완성발관。대환자완성1개월적치료지후，대환자혈청CA125진행복사，병차대환자실시흉복분강CT검사，선택RECIST료효평개표준대환자최종적림상치료효과실시평개。결과：대환자완성1개월적치료후，재소유환자중，완전완해환자5례，은정환자36례，진전환자1례。환자근기총유효솔위97.6%（41/42）。대환자진행위기2년적수방，환자무진전생존기시간위6～25개월，평균진전생존기시간위（12.3±0.1）개월。소유환자전부성공완성일차성천자，대환자림상실시수술적시간위26～47 min，평균시간위（36.5±1.2）min。결론：침대복발성란소암환자，림상우 CT 인도하，선택경피천자관주순박진행치료，최종우림상능구획득학절치료효과，표현출교고적치료안전성，철현차충방법치료복발성란소암환자적림상개치。
Objective: To investigate effects of CT-guided percutaneous perfusion of cisplatin on recurrent ovarian cancer. Methods: 42 cases with recurrent ovarian cancer treated in our hospital form May 2012 to May 2014 all were adopted CT-guided percutaneous perfusion of cisplatin on ovarian tumors. Upon successful completion of catheterization, patients were given perfusion dose of 20 mg of cisplatin, 1 times / week, for four weeks continuously, and then extubated. After patients completed a month of treatment, we performed examination on patients’ serum CA125 and abdominal and pelvic CT scan and evaluated clinical effects with RECIST Response Evaluation Criteria. Results: After a month of treatment, 5 patients got complete remission, 36 patients got stable and 1 patient got progressed. The total efficacy of patients was 97.6% (41/42). Patients were followed up for 2 years, patients’ progression-free survival time was 6 months -25 months, with an average of (12.3 ± 0.1) months. All patients completed a successful one-time puncture and the clinical surgery lasted for 26 minutes -47 minutes, with an average of (36.5 ± 1.21) minutes.Conclusion: For patients with recurrent ovarian cancer, CT-guided percutaneous perfusion of cisplatin shows exact clinical effects and higher therapeutic safety, highlighting clinical value of such a therapy to treat recurrent ovarian cancer.